A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
A genomic test for successfully predicting whether cancer will resist common types of chemotherapy has been developed. Cancer Research UK (CRUK) funded scientists at the University of Cambridge (UK), ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
Metropolis Healthcare has launched a Centre for Genomics to expand its specialty diagnostics business. The company plans to ...
Today, the Nature Health journal has published Monash University’s DNA Screen study results. The study piloted the idea of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback